Logo
Kairax Sub Q 1 x 1 ml

Kairax Sub Q 1 x 1 ml

Kairax

Derma fillers
  • CE Marked hyaluronic acid dermal filler (Class III medical device) for aesthetic indications, as stated by Kairax and multiple distributors
  • Manufactured under a medical device quality management system meeting EU safety and performance requirements for injectable HA implants
  • Contains 100% biodegradable, biocompatible components compliant with applicable regulatory standards
Hyaluronic acid dermal filler for deep volume and contouring

Description

Kairax Sub Q 1 x 1 ml is a high-viscosity, cross-linked hyaluronic acid dermal filler with 0.3% lidocaine, designed for restoring deep facial volume and providing long-lasting facial contouring. As the highest-viscosity product in the Kairax range, Sub Q is ideal for volumising and defining areas such as the cheeks, jawline and nasolabial folds. The filler is fully CE approved, offers minimal swelling and bruising, and delivers smooth, natural-looking, youthful results. Each box contains one 1 ml prefilled syringe and two 25G needles for injection by trained professionals.

Bnefits

  • High-viscosity HA filler specifically designed for deep-volume restoration and contouring
  • Contains 24 mg/ml cross-linked hyaluronic acid for robust structural support
  • Includes 0.3% lidocaine to reduce pain and swelling during and after the procedure
  • Highest viscoelasticity in the Kairax range, meaning it holds its shape effectively for volumising and sculpting
  • Effectively restores volume to deep facial areas such as cheeks, jawline and nasolabial folds
  • Provides smooth, natural-looking facial contours with minimal swelling and bruising
  • Results typically last between 6–12 months, depending on individual patient factors and treatment area
  • Made from 100% biodegradable, biocompatible components that are gradually resorbed by the body
  • Fully CE approved HA filler giving assurance of quality and safety standards

Indications

  • Restoration of lost facial volume in deep tissue planes
  • Volumising and contouring of cheeks and malar region
  • Definition and shaping of jawline and chin
  • Filling of deep nasolabial folds and other deep facial wrinkles
  • Selected body contouring indications where an experienced practitioner deems appropriate, as described by the brand (e.g. small-volume correction)

Composition

  • Cross-linked hyaluronic acid 24 mg/ml
  • Lidocaine hydrochloride 0.3% for local anaesthesia
  • Physiological buffer solution and water for injection (exact excipient list not fully detailed in public summaries)

Formulation

  • Sterile, pyrogen-free, viscoelastic gel of cross-linked, non-animal hyaluronic acid
  • HA concentration: 24 mg/ml with 0.3% lidocaine
  • Highest viscoelasticity in the Kairax range (approx. 350–450 Pa, as stated in some distributor descriptions)
  • Designed for injection into the mid to deep dermis and/or subcutaneous layer depending on the anatomical area and technique
  • Single-use prefilled 1 ml syringe with luer-lock connection
  • Intended for administration by qualified medical/aesthetic professionals only

Packaging

  • Box contains: 1 x 1 ml prefilled syringe of Kairax Sub Q
  • 2 x 25G x 12 mm sterile single-use needles supplied in the box (as per Kairax range specification)
  • Sterile blister tray housing the syringe and needles
  • External carton printed with product name, volume, batch number, expiry date, CE mark and basic usage information

Usage

  • For professional use only by appropriately trained and qualified healthcare practitioners experienced in dermal filler injection.
  • Review the patient’s medical history, indications and contraindications; obtain informed consent before treatment.
  • Cleanse and disinfect the treatment area following local aseptic protocols.
  • Kairax Sub Q is typically injected into the mid to deep dermis or subcutaneous tissue for volumising and contouring, using linear or linear-retrograde techniques as recommended by the manufacturer.
  • Recommended needle: 25G x 12 mm (supplied) or appropriate cannula according to practitioner preference and anatomical considerations.
  • Inject slowly and with minimal pressure, aspirating in accordance with current best practice and injector training to reduce the risk of intravascular injection.
  • Carefully sculpt and mould the product after injection if necessary to achieve smooth, natural contours; avoid overcorrection.
  • Typical results last around 6–12 months, after which touch-up or repeat treatments may be performed as clinically indicated.
  • Dispose of used syringe, needles and any remaining product in an approved sharps container; do not resterilise or reuse.

Contraindications

  • Hypersensitivity or allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics or any component of the product
  • History of severe allergy or anaphylactic reactions
  • Known hypersensitivity to Gram-positive bacterial proteins (source of HA production)
  • Active skin infections, inflammation or lesions at or near the intended injection sites
  • Autoimmune diseases or immunosuppressive therapy, unless carefully evaluated and approved by a physician
  • Bleeding disorders or current use of strong anticoagulant/antiplatelet therapy without appropriate risk assessment
  • Pregnancy and breastfeeding (generally not recommended due to limited safety data)
  • Children and adolescents (intended for adults only)
  • Injection into blood vessels or in areas with compromised vascularity is strictly contraindicated due to risk of serious complications

Adverse Effects

  • Common, transient injection-site reactions including redness, swelling, pain, tenderness, itching, bruising or discolouration at the treated area
  • Temporary nodules, lumps or firmness which typically resolve with time or gentle massage, if advised by the practitioner
  • Rare inflammatory or hypersensitivity reactions, including prolonged swelling or induration
  • Very rare but serious complications associated with inadvertent intravascular injection, such as vascular occlusion, tissue ischaemia or necrosis, and visual disturbances
  • Small risk of infection at injection sites if aseptic technique and aftercare instructions are not strictly followed

Storage Conditions

  • Store in the original packaging at a controlled room temperature as indicated on the box (typically between 2 °C and 25 °C).
  • Protect from freezing and from direct sunlight or excessive heat.
  • Keep the syringe and needles in their sterile blister until immediately before use to maintain sterility.
  • Do not use the product after the expiry date printed on the packaging or if the sterile blister or syringe appears damaged.

Duration

Clinical and distributor information report typical durability of effects between 6 and 12 months, depending on individual patient metabolism, treatment area and injection technique.

Onset

Immediate visible restoration of volume and contour following injection, with final results refined over several days as any swelling or minor bruising resolves.

Browse more Derma fillers

Top Treatments

Top Cities in the UK